



One Boston Medical Center Place
Boston, Massachusetts 02118-2909

STATEMENT OF INTENT

TO ESTABLISH A CONSORTIUM / SUBAWARD AGREEMENT WITH

BMC InfoEd#:

Originating Sponsor:	<input type="text"/>
Prime Applicant (PTE):	<input type="text"/>
Prime PI Name:	<input type="text"/>
Project Title:	<input type="text"/>

Subrecipient/Cooperating Institution:	Boston Medical Center Corporation	TIN (NIH EIN):	04-3314093 (1-043314093-A1)
BMC PI:	<input type="text"/>	MPI on proposal?	<input type="text"/>
		eRA Commons ID:	<input type="text"/>
PI Tel.:	<input type="text"/>	PI Fax:	<input type="text"/>
		PI E-mail:	<input type="text"/>
Initial Budget Period:	<input type="text"/>	to	<input type="text"/>
		Total Direct Costs:	<input type="text"/>
		MTDC	<input type="text"/>
		F&A Rate	<input type="text"/>
		F&A Costs:	<input type="text"/>
		Total Costs:	<input type="text"/>
Entire Project Period:	<input type="text"/>	to	<input type="text"/>
		Total Direct Costs:	<input type="text"/>
		MTDC	<input type="text"/>
		F&A Rate	<input type="text"/>
		F&A Costs:	<input type="text"/>
		Total Costs:	<input type="text"/>

BMC Institutional Business Official to be Notified in Case of an Award

Name and Title:	<input type="text"/>						
Address:	960 Massachusetts Avenue, 2 nd Floor, Boston, Massachusetts 02118-2690						
Tel.:	(617) 414-2628	Fax:	(617) 414-2834	Central E-mail:	Grants.Admin@bmc.org	GCA:	<input type="text"/>
SAM.gov UEI:	JZ8RQC4EMDZ5	Active through:	06/29/2024	DUNS:	00-549-2160	Congressional District:	MA-007
Organization Type:	"M": Not-for-profit institution with IRS 501(c)(3) status, other than an institute of higher education						

Project Information and Assurances	Assurance Number	Pending	Approval Date
Human Subjects	FWA 00023612	<input type="checkbox"/>	
Vertebrate Animals	D16-002014 (A3316-01)	<input type="checkbox"/>	
Human Embryonic Stem Cells (hESCs)		<input type="checkbox"/>	
Program Income		<input type="checkbox"/>	

Certifications

In signing below and offering to participate in this research program, Boston Medical Center Corporation (BMC) certifies that (1) neither it is nor its principals are presently debarred, suspended, proposed for debarment, declared ineligible or voluntarily excluded from receiving funds from any federal department or agency and is not delinquent on any federal debt; (2) it is in compliance with the Drug Free Workplace Act of 1988; (3) it is in compliance with U.S. Code, Section 1352, restrictions on the use of federal funds for the purpose of lobbying; (4) it has filed annually with the Office of Scientific Integrity a PHS form 6349 governing Misconduct in Science; (5) it has filed with DHHS compliance offices certification forms governing Civil Rights (441), Handicapped Individuals (641), Sex Discrimination (639-A), and Age Discrimination (680); (6) it is in compliance with PHS policy governing Program Income; they have established policies in compliance with 45 CFR Part 46, Subpart A (protection of human subjects); the Animal Welfare Act (PL-89-544 as amended) and the Health Research Extension Act of 1985 (Public Law 99-158); and that (7) it is in compliance with NIH guidelines regarding human pluripotent stem cell research, transplantation of fetal tissue, recombinant DNA and human gene transfer research, and inclusion of women, children & minorities in research.

The appropriate programmatic and administrative personnel of each institution involved in this grant application are aware of the PHS-NIH consortium grant policies and are prepared to establish the necessary inter-institutional agreements consistent with those policies. In signing below, Boston Medical Center Corporation (BMC) certifies it has implemented and is enforcing a written policy of conflicts of interest consistent with the provisions of 42 CFR Part 50, Subpart F & 45 CFR Subtitle A, Part 94. If a conflict is identified by BMC during the period of the award contemplated under this agreement, BMC will report to the Prime Awardee the existence of the conflict, including the grant title, PI (if different from the investigator with the financial interest) and the specific method BMC adopts for addressing the conflict (managing, reducing, or eliminating it). BMC will rely on the Prime Awardee to report the existence of the conflict to NIH.

**BOSTON MEDICAL CENTER CORPORATION BUSINESS OFFICIAL
AUTHORIZED ORGANIZATION REPRESENTATIVE (AOR)**

DATE

The Statement of Work (SoW) should provide sufficient detail about the proposed work to allow an individual reviewing the statement and who is/was familiar with the project to determine whether or not the work agreed to was actually performed. Include objectives, tasks and deliverables as applicable.

For Federal Funding Accountability and Transparency Act (FFATA) compliance and reporting, the SoW should be limited to no more than 4000 characters.

Please type or copy and paste the statement of work in the area below.